Some studies have shown decreased SHP-1 expression was associated with poor outcome in prostate cancer (Tassidis et al. 2010), colorectal cancer (Fan et al. 2016), and triple-negative breast cancer (Liu et al. 2017b, c), whereas other studies demonstrated contrarily that increased SHP-1 expression is associated with recurrence in nasopharyngeal carcinoma (Peng et al. 2014) or aggressiveness in breast cancer (Insabato et al. 2009). This evidence concerns the gene PTPN6 and breast carcinoma.